Replies to post #6203 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Jp2011, asI understand it, it appears to be a way of piggy backing on previous filing to extend the patent portfolio associated to a product. For instance by adding new claims but maintaining the contiuity of the previous claims. If you lose continuity and were to submit a new patent application , the examiner could use anything published up until the date of the new submission to reject by assigning prior art to a more recent invention publication covering the same claim. By claiming the benefit only the new claims are affected by the new submission date. The previous claims are still bound by earlier filings. In ANIP case the CV risk reduction claims can only be rejected with published information prior to the 2010 provisional submission

In the case of Abbvie and ANI, given that Dr Snabes works for Abbvie. That it appears that someone other then ANI analyzed the data from Libigel safety/Efficacy study that led to adding the claim of Breast Cancer risk reduction.

When you see that both Abbvie and Anip filed new patent applications on the same day October 21, 2016 .

Abbvie's their testosterone patent titled PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM (FOR MEN)

ANI's patent titled Methods for treating sexual dysfunction while decreasing cardiovascular risk (FOR WOMEN)

The last time they touched the patent was mid 2015 but filing was abandoned as earlier 2103 applications were patented.

North, if I am misinterpreting this, please step in.

Jp2011, Now put it into the context with teh following:

1) Libigel removing the Deals.Bio page listing Libigel as an opportunity

2) Ani letting the Libigel Trademark expire.

3) The CVRs showing up in Shareholders trading accounts in August 2015 when they were non existent since June 2013 when they were issued.

4) August 19, 2015 -Abbvie acquires the Priority Review Voucher from United Therapeutics for $350 million, the day after Addyi is approved as the first drug to treat HSDD for pre-menopausal women (Libgel is for postmenopausal women)

5) Dentons accidentally files a response to the USPTO as a Large entity overpaying their fee. Possibly an honest mistake, but info was coming from Abbvie to justify the breast cancer claims, than i can see how this was easily overlooked. Had they not filed to recover the fee over-payment, I may not have noticed it.

Just my observations, I leave it to you to draw your own conclusions.